evidence limit
EXONDYS 51: non-DMD CrCl thresholds do not settle DMD renal dosing
Reduced muscle mass limits transfer of creatinine-based study thresholds to DMD. The source cannot recommend a specific renal adjustment.
What to reconcileTreat the missing regimen as an evidence gap requiring specialist assessment, not no-adjustment permission.
1 source identities and dates
GlobalRPh RX List - EXONDYS 51GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Duchenne muscular dystrophy; renal PK was studied outside the DMD population. No patient-specific dose adjustment is established by this card.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.5.
combination metric and currency hold
Use the fixed-combination table only with its source qualifications
The retrieved dated label has different infusion times by renal category, ambiguous printed MDRD units and an ended marketing entry.
What to reconcileConfirm the current exact product and units; retain this as a qualified snapshot, not a cefepime-only substitute.
1 source identities and dates
EXBLIFEP - cefepime and enmetazobactam injectionDailyMed / Allecra Therapeutics SAS | Source revision: 2/2024
EXBLIFEP fixed-combination intravenous cefepime/enmetazobactam for its adult indication; not single-agent cefepime. Dated label/currency review remains open.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.8.
formulation scope
Exenatide: immediate- and extended-release renal cutoffs differ
BYDUREON BCISE uses an indexed-eGFR restriction, whereas the retained BYETTA source uses CrCl and product-specific cautions. These are different product instructions, not numbers to reconcile by averaging.
What to reconcileChoose the exact release formulation and matching renal measure, and retain volume-depletion monitoring.
1 source identities and dates
GlobalRPh RX List - BYDUREON BCISEGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
BYDUREON BCISE extended-release exenatide, not immediate-release BYETTA.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.5.
source scope and renal guidance
Before use: Febuxostat (ULORIC, adults)
Fresh official labeling adds the renal cap together with the cardiovascular and treatment-selection restrictions; the earlier RX source remains separately dated.
What to reconcileCheck the allopurinol treatment history, cardiovascular risk, renal range and interacting medicines before applying the renal limit.
1 source identities and dates
Febuxostat - ULORIC official renal restrictionsDailyMed / NLM exact product labeling | Source revision: 4/2023
Adults with gout when maximally titrated allopurinol is inadequate, not tolerated or not advisable.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v6.4.
procedure preparation scope
Renal issue concerns preparation, not the microbiota capsule dose
VOWST describes a trial alternative for patients with impaired kidney function unable to take magnesium citrate. The source labels the polyethylene-glycol electrolyte preparation use as unapproved for this purpose.
What to reconcileReview laxative suitability, volume/electrolyte considerations and the complete administration timeline. Do not assume every renal patient requires the trial alternative or infer a VOWST dose reduction.
1 source identities and dates
GlobalRPh RX List - VowstGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
VOWST adult recurrent C. difficile prevention; renal consideration concerns bowel preparation, not an invented capsule-dose change.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.0.
source quality hold
Source-identity hold: title strength does not match capsule description
The separate RX fenofibrate-drug page is titled 40/120 mg but describes 50/150 mg capsules. No renal dosing from that mismatched page was imported in v4.1.
What to reconcileUse the verified named-product source, not the held generic page. See the F audit entry for its retrieval reference. This is a source-quality problem, not a clinical disagreement.
1 source identities and dates
GlobalRPh RX List - TRICORGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Fenofibrate TRICOR tablets, 48/145 mg.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.1.
formulation difference
Fenofibrate renal starting strengths are product-specific
TRICOR uses its own starting strength. ANTARA, LIPOFEN and FENOGLIDE have different strengths; TRIGLIDE has a distinct lower-dose availability restriction.
What to reconcileConfirm the dispensed formulation and its own renal instructions. Do not apply a generic milligram-equivalence rule.
1 source identities and dates
GlobalRPh RX List - TRICORGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Fenofibrate TRICOR tablets, 48/145 mg.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.1.
formulation difference
Do not manufacture a lower TRIGLIDE strength
The source does not recommend TRIGLIDE in the moderate eGFR range because a lower dose is not available. Other fenofibrate brands supplying lower strengths are distinct products.
What to reconcileSelect an actual suitable formulation rather than applying another brand's dose to TRIGLIDE.
1 source identities and dates
GlobalRPh RX List - TRIGLIDEGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
TRIGLIDE formulation; lower-dose product availability governs its renal restriction.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.1.
formulation difference
Fenofibric-acid tablets are not delayed-release capsules
The newly stored FIBRICOR tablet renal instruction is specific to its 35/105 mg strengths. The existing TRILIPIX record concerns delayed-release capsules.
What to reconcileKeep formulation and renal starting strength together; review the linked capsule source separately.
1 source identities and dates
GlobalRPh RX List - FIBRICORGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Fenofibric acid FIBRICOR tablets, 35/105 mg; not TRILIPIX delayed-release capsules.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.1.
formulation and population difference
A renal starting-dose reduction does not establish patch eligibility
The renal instruction applies to a transdermal product reserved for already opioid-tolerant patients. It is not a starting opioid or a substitute IV fentanyl rule.
What to reconcileVerify opioid tolerance, formulation and complete conversion instructions before applying the renal adjustment.
1 source identities and dates
GlobalRPh RX List - DURAGESICGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Transdermal fentanyl for already opioid-tolerant patients; not IV or transmucosal fentanyl.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.1.
population and metric difference
Adult CrCl and pediatric eGFR restrictions differ
The adult table contains a 4 mg row below CrCl 15, while pediatric recommendations differ by weight and do not recommend treatment below eGFR 15 or during dialysis.
What to reconcileMatch age, weight, renal measure and CYP3A4 interactions; never carry the adult low-clearance row into pediatric NDO.
1 source identities and dates
GlobalRPh RX List - TOVIAZGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Extended-release TOVIAZ; adults with OAB versus children >=6 years with NDO and weight >25 kg.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.1.
combination product difference
Combination restriction cannot be borrowed from finasteride alone
ENTADFI is not recommended below CrCl 50 or on hemodialysis. Finasteride monotherapy guidance does not account for the tadalafil component.
What to reconcileUse the combination-product restriction rather than clearing treatment using a single component.
1 source identities and dates
GlobalRPh RX List - ENTADFIGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Fixed 5 mg finasteride / 5 mg tadalafil capsules for initial BPH treatment; not either component alone.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.1.
indication and label version difference
CKD target and newer HF target are not interchangeable
The RX CKD source targets 20 mg daily. The separately stored August 2025 label adds an HF target that depends on initiation eGFR and can reach 40 mg.
What to reconcileDetermine the indication and use its full potassium/eGFR adjustment table. The new HF card is a start/target summary, not every Table 3 restart cell.
1 source identities and dates
GlobalRPh RX List - KERENDIAGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Retrieved RX version covers CKD associated with type 2 diabetes, not the newer separate HF target.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.1.
monitoring scope difference
HF target is not an automatic escalation instruction
The stored HF card contains starting and target doses but intentionally does not reproduce every potassium-based hold/restart cell.
What to reconcileReview the complete HF Table 3 before titration; do not use the CKD-only target or treat reaching the target as automatic.
1 source identities and dates
Finerenone tablets (KERENDIA, HF with LVEF >=40%)DailyMed / Bayer HealthCare Pharmaceuticals Inc. | Source revision: 8/2025; SPL effective 2025-08-28
Adult HF with LVEF >=40%; separate from CKD with type 2 diabetes. Starting/target summary, not the full Table 3 titration algorithm.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.1.
indication or treatment phase
HF potassium adjustment is now stored separately from CKD titration
A new official-source supplement includes the HF Table 3 dose actions and footnotes. The preserved earlier HF card remains a starting/target summary. HF potassium thresholds differ from CKD Table 2.
What to reconcileRead the HF Table 3 supplement with the original eligibility/target card and current label. Do not apply CKD hold/restart thresholds to HF. New content remains pending independent review.
1 source identities and dates
KERENDIA HF - potassium adjustment Table 3 supplementDailyMed / Bayer HealthCare Pharmaceuticals Inc. | Source revision: August 2025
Adults with HF and LVEF >=40%; supplement to the preserved starting/target-dose card, not CKD Table 2.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.2.
source scope and renal guidance
Before use: Flecainide acetate - conventional oral tablets
Both sources print indexed CrCl. Do not silently replace it with an unindexed cutoff or combine this initiation schedule with acute conversion dosing.
What to reconcileConfirm the exact product, indication, renal measure and full source before prescribing.
2 source identities and dates
GlobalRPh RX List - TambocorGlobalRPh-hosted RX List | Source revision: Revision not established in selected retrieval
Selected adult maintenance-therapy initiation guidance, not a pill-in-the-pocket protocol.
Read this stored source Flecainide acetate - conventional oral tabletsDailyMed / NLM exact product labeling | Source revision: Revision not established in selected retrieval
Selected adult maintenance-therapy initiation guidance, not a pill-in-the-pocket protocol.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v6.3.